Página 1 dos resultados de 1272 itens digitais encontrados em 0.024 segundos

Effectiveness of a mass immunization campaign against serogroup C meningococci in children in the Federal State of Santa Catarina, Brazil

Kupek,Emil; Puricelli,Rubens C. B.; Westrupp,Maria Helena B.
Fonte: Brazilian Society of Infectious Diseases Publicador: Brazilian Society of Infectious Diseases
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/12/2001 EN
Relevância na Pesquisa
56.44%
In addition to vaccine efficacy studies, there is a pressing need to evaluate vaccine effectiveness in a way that takes into account the limitations of health care systems in certain settings. An attempt to reach this objective was exemplified by a vaccination campaign against serogroup C meningococci in the federal state of Santa Catarina, in Brazil. A polysaccharide vaccine against serogroup C meningococci was administered to all individuals between 6 months and 14 years of age in March, 1996, in the municipalities that had the highest incidence of meningococcal disease in the previous year. All cases of the disease due to this serogroup observed in Santa Catarina during a 1-year period before and after the vaccination were included in the analysis. The cumulative incidence rate ratio was calculated for the unvaccinated compared to the vaccinated area. As a second step, the ratio of this quantity for the period before and after the vaccination, i.e. the ratio of the rate ratios (RRR), was calculated. One minus RRR was used to estimate the vaccine effectiveness. In the general population, the vaccine effectiveness was 74.3% (95% confidence intervals 52.7% to 99.6%). In children 6 months to 14 years, vaccine effectiveness was 93.1% (85.2% to 100%). Vaccine effectiveness could not be confirmed within more specific age bands...

Moderate influenza vaccine effectiveness in Victoria, Australia, 2011

Fielding, J E; Grant, K A; Tran, T; Kelly, H A
Fonte: European Centre for Disease Prevention and Control Publicador: European Centre for Disease Prevention and Control
Tipo: Artigo de Revista Científica Formato: 5 pages
Relevância na Pesquisa
66.29%
We used a sentinel general practitioner (GP) network to conduct surveillance for laboratory-confirmed influenza amongst patients presenting with influenza-like illness (ILI) in Victoria, Australia in 2011. The test-negative variation of the case control study design was used to estimate effectiveness for seasonal trivalent influenza vaccine. Cases and controls were ILI patients that tested positive and negative for influenza, respectively. Vaccination status was recorded by GPs and vaccine effectiveness (VE) was calculated as (1-adjusted odds ratio)x100%. There were 529 patients included in the study, of which 29% were influenza-positive. Twelve percent of study participants were reported as vaccinated, 6% of cases and 15% of controls. Adjusted VE against all influenza was 56%, but not statistically significant. There was generally little variation in VE estimates when stratified by virus type and subtype, which is consistent with good matches between circulating strains and the vaccine strains. The VE was higher among adults of working age than among children.

Estimation of type- and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-2008

Fielding, James E; Grant, Kristina A; Papadakis, Georgina; Kelly, Heath A
Fonte: BioMed Central Publicador: BioMed Central
Tipo: Artigo de Revista Científica Formato: 9 pages
Relevância na Pesquisa
66.26%
Background Antigenic variation of influenza virus necessitates annual reformulation of seasonal influenza vaccines, which contain two type A strains (H1N1 and H3N2) and one type B strain. We used a test negative case control design to estimate influenza vaccine effectiveness (VE) against influenza by type and subtype over two consecutive seasons in Victoria, Australia. Methods Patients presenting with influenza-like illness to general practitioners (GPs) in a sentinel surveillance network during 2007 and 2008 were tested for influenza. Cases tested positive for influenza by polymerase chain reaction and controls tested negative for influenza. Vaccination status was recorded by sentinel GPs. Vaccine effectiveness was calculated as [(1 - adjusted odds ratio) × 100%]. Results There were 386 eligible study participants in 2007 of whom 50% were influenza positive and 19% were vaccinated. In 2008 there were 330 eligible study participants of whom 32% were influenza positive and 17% were vaccinated. Adjusted VE against A/H3N2 influenza in 2007 was 68% (95% CI, 32 to 85%) but VE against A/H1N1 (27%; 95% CI, -92 to 72%) and B (84%; 95% CI, -2 to 98%) were not statistically significant. In 2008, the adjusted VE estimate was positive against type B influenza (49%) but negative for A/H1N1 (-88%) and A/H3N2 (-66%); none was statistically significant. Conclusions Type- and subtype-specific assessment of influenza VE is needed to identify variations that cannot be differentiated from a measure of VE against all influenza. Type- and subtype-specific influenza VE estimates in Victoria in 2007 and 2008 were generally consistent with strain circulation data.; The sentinel general practice surveillance program is funded by the Victorian Government Department of Health.

Pandemic influenza H1N1 2009 infection in Victoria, Australia: No evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009

Kelly, Heath A; Grant, Kristina A; Fielding, James E; Carville, Kylie S; Looker, Clare O; Tran, Thomas; Jacoby, Peter
Fonte: Elsevier Publicador: Elsevier
Tipo: Artigo de Revista Científica Formato: 8 pages
Relevância na Pesquisa
56.27%
Conflicting findings regarding the level of protection offered by seasonal influenza vaccination against pandemic influenza H1N1 have been reported. We performed a test-negative case control study using sentinel patients from general practices in Victoria to estimate seasonal influenza vaccine effectiveness against laboratory proven infection with pandemic influenza. Cases were defined as patients with an influenza-like illness who tested positive for influenza while controls had an influenza-like illness but tested negative. We found no evidence of significant protection from seasonal vaccine against pandemic influenza virus infection in any age group. Age-stratified point estimates, adjusted for pandemic phase, ranged from 44% in persons aged less than 5 years to −103% (odds ratio = 2.03) in persons aged 50–64 years. Vaccine effectiveness, adjusted for age group and pandemic phase, was 3% (95% CI −48 to 37) for all patients. Our study confirms the results from our previous interim report, and other studies, that failed to demonstrate benefit or harm from receipt of seasonal influenza vaccine in patients with confirmed infection with pandemic influenza H1N1 2009.; This study was supported in part by the National Health and Medical Research Council Strategic Awards...

Understanding influenza vaccine protection in the community: an assessment of the 2013 influenza season in Victoria, Australia

Carville, Kylie S.; Grant, Kristina A.; Sullivan, Sheena G.; Fielding, James E.; Lane, Courtney R.; Franklin, Lucinda; Druce, Julian; Kelly, Heath A.
Fonte: Elsevier Publicador: Elsevier
Tipo: Artigo de Revista Científica Formato: 6 pages
Relevância na Pesquisa
56.27%
BACKGROUND The influenza virus undergoes frequent antigenic drift, necessitating annual review of the composition of the influenza vaccine. Vaccination is an important strategy for reducing the impact and burden of influenza, and estimating vaccine effectiveness (VE) each year informs surveillance and preventative measures. We aimed to describe the influenza season and to estimate the effectiveness of the influenza vaccine in Victoria, Australia, in 2013. METHODS Routine laboratory notifications, general practitioner sentinel surveillance (including a medical deputising service) data, and sentinel hospital admission surveillance data for the influenza season (29 April to 27 October 2013) were collated in Victoria, Australia, to describe influenza-like illness or confirmed influenza during the season. General practitioner sentinel surveillance data were used to estimate VE against medically-attended laboratory confirmed influenza. VE was estimated using the case test negative design as 1-adjusted odds ratio (odds of vaccination in cases compared with controls) × 100%. Cases tested positive for influenza while non-cases (controls) tested negative. Estimates were adjusted for age group, week of onset, time to swabbing and co-morbidities. RESULTS The 2013 influenza season was characterised by relatively low activity with a late peak. Influenza B circulation preceded that of influenza A(H1)pdm09...

Influenza vaccine effectiveness in Portugal: season 2014/2015 report; Efetividade da vacina antigripal em Portugal: época 2014/2015

Machado, Ausenda; Ambrósio Rodrigues, Ana Paula; Guiomar, Raquel; Pechirra, Pedro; Nunes, Baltazar
Fonte: National Health Institute Doutor Ricardo Jorge Publicador: National Health Institute Doutor Ricardo Jorge
Tipo: Relatório
Publicado em 06/10/2015 ENG
Relevância na Pesquisa
66.42%
This report was prepared as part of the Project “Monitoring Influenza vaccine effectiveness during influenza seasons and pandemics in the European Union”, financed by the European Centre for Disease Prevention and Control, and describes the results obtained in Portugal under the Protocol Agreement celebrated between EpiConcept SARL, Paris and National Health Institute Doutor Ricardo Jorge, Lisbon, signed on December 2014.; Relatório elaborado em julho de 2015.; [eng] Background: The EuroEVA project is the Portuguese component of the multicentre I-MOVE study. The results to be presented are related to the 7th EuroEVA season and aimed the estimation of 2014-15 end of season influenza vaccine effectiveness in i) all age groups; ii) by risk group; iii) by influenza subtype and thus contribute to monitor VE estimates every year. Material and methods: The “Protocol for case-control studies to measure seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States- Portuguese site study version” was implemented entirely with no changes to be added. VE was estimated as one minus the odds ratio of being vaccinated in cases versus controls adjusted for confounders by logistic regression. Potential confounders were investigated and included if they changed crude OR estimate in at least 10% after adjustment by the Mantel-Haenszel method. Results: In Portugal...

I-Move towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in europe, 2008-9

Kissling, E.; Valenciano, M.; Falcao, J.; Larrauri, A.; Widgren, K.; Pitigoi, D.; Oroszi, B.; Nunes, Baltazar; Savulescu, C.; Mazick, A.; Lupulescu, E.; Ciancio, B.; Moren, A.
Fonte: European Centre for Disease Prevention and Control Publicador: European Centre for Disease Prevention and Control
Tipo: Artigo de Revista Científica
Publicado em /11/2009 ENG
Relevância na Pesquisa
66.21%
Within I-MOVE (European programme to monitor seasonal and pandemic influenza vaccine effectiveness (IVE)) five countries conducted IVE pilot case-control studies in 2008-9. One hundred and sixty sentinel general practitioners (GP) swabbed all elderly consulting for influenza-like illness (ILI). Influenza confirmed cases were compared to influenza negative controls. We conducted a pooled analysis to obtain a summary IVE in the age group of >or=65 years. We measured IVE in each study and assessed heterogeneity between studies qualitatively and using the I2 index. We used a one-stage pooled model with study as a fixed effect. We adjusted estimates for age-group, sex, chronic diseases, smoking, functional status, previous influenza vaccinations and previous hospitalisations. The pooled analysis included 138 cases and 189 test-negative controls. There was no statistical heterogeneity (I2=0) between studies but ILI case definition, previous hospitalisations and functional status were slightly different. The adjusted IVE was 59.1% (95% CI: 15.3-80.3%). IVE was 65.4% (95% CI: 15.6-85.8%) in the 65-74, 59.6% (95% CI: -72.6 -90.6%) in the age group of >or=75 and 56.4% (95% CI: -0.2-81.3%) for A(H3). Pooled analysis is feasible among European studies. The variables definitions need further standardisation. Larger sample sizes are needed to achieve greater precision for subgroup analysis. For 2009-10...

Influenza Vaccine Effectiveness in Portugal: Season 2011-12. Final Report

Nunes, Baltazar; Guiomar, Raquel; Machado, Ausenda; Pechirra, Pedro; Gonçalves, Paulo; Conde, Patrícia; Batista, Inês; João, Inês; Falcão, Isabel
Fonte: Instituto Nacional de Saúde Doutor Ricardo Jorge, IP Publicador: Instituto Nacional de Saúde Doutor Ricardo Jorge, IP
Tipo: Relatório
Publicado em /08/2012 ENG
Relevância na Pesquisa
66.36%
The EuroEVA project is the Portuguese component of the multicentre I-MOVE study and aims to obtain estimates of the seasonal and pandemic vaccine effectiveness during and after the influenza season. Since the 2008/2009 influenza season Portugal, along with other European countries, has implemented a common protocol using a case-control study design, where influenza-like illness cases which are laboratory confirmed as influenza (ILI+) are compared to a control group consisting of ILI patients which test negative for influenza (ILI-) (Case-control Test negative design). The results presented in this report relate to the EuroEVA 2011-2012 season and aim to estimate the seasonal influenza vaccine effectiveness for the age group 60+ years and in all age groups, using two approaches: Case-control Test negative design and Screening Method. Materials and Methods Test Negative Design ILI cases were identified among patients that presented ILI symptoms to a participating EuroEVA General Medical Practitioner (GP). On a weekly basis, each GP systematically selected ILI patients (two per week with less than 60 years and all ILI patients with 60 years and more) using the EU ILI case definition. Data on potential confounding factors and effect modifiers was collected using a standardized questionnaire which included information on socio-demographic variables (age...

Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case-control study, 2011/12

Kissling, E.; Valenciano, M.; I-MOVE, Case-Control Studies Team
Fonte: ECDC_European Centre for Disease Prevention and Control Publicador: ECDC_European Centre for Disease Prevention and Control
Tipo: Artigo de Revista Científica
Publicado em 12/04/2012 ENG
Relevância na Pesquisa
66.17%
Colaboração de: Baltazar Nunes, investigador do DEP; To provide an early estimate of 2011/12 influenza vaccine effectiveness (VE), we conducted a multicentre case–control study based on seven sentinel surveillance networks. We included influenza-like illness cases up to week 7/2012 from the vaccination target groups, swabbed less than eight days after symptom onset. Laboratory-confirmed influenza A(H3) cases were compared to negative controls. Adjusted VE was 43% (95% confidence interval: -0.4 to 67.7), suggesting low to moderate VE against influenza A(H3) in the early 2011/12 season.

Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13

Valenciano, M.; Kissling, E.; I-MOVE Case-Control Study Team
Fonte: ECDC-European Centre for Disease Prevention and Control Publicador: ECDC-European Centre for Disease Prevention and Control
Tipo: Artigo de Revista Científica
Publicado em 14/02/2013 ENG
Relevância na Pesquisa
56.1%
Baltazar Nunes: member of the I-MOVE case–control study team; We conducted a test-negative case–control study based in five European sentinel surveillance networks. The early 2012/13 adjusted influenza vaccine effectiveness was 78.2% (95% CI: 18.0 to 94.2) against influenza B, 62.1% (95% CI: −22.9 to 88.3%) against A(H1)pdm09, 41.9 (95% CI: −67.1 to 79.8) against A(H3N2) and 50.4% (95% CI: −20.7 to 79.6) against all influenza types in the target groups for vaccination. Efforts to improve influenza vaccines should continue to better protect those at risk of severe illness or complications.

Influenza vaccine effectiveness 2010-11 in Portugal obtained by two methods: results from the EuroEVA study

Machado, Ausenda; Nunes, Baltazar; Pechirra, Pedro; Gonçalves, Paulo; Conde, Patricia; Guiomar, Raquel; Falcão, Isabel
Fonte: Instituto Nacional de Saúde Doutor Ricardo Jorge, IP Publicador: Instituto Nacional de Saúde Doutor Ricardo Jorge, IP
Tipo: Conferência ou Objeto de Conferência
Publicado em /11/2011 ENG
Relevância na Pesquisa
66.39%
Resumo publicado em: European Scientific Conference on Applied Infectious Disease Epidemiology: abstract book. ECDC, 2011, p. 146; Background: Every year the influenza vaccine is reformulated so estimating the influenza vaccine effectiveness (VE) every season and in an early stage is important to support public health decisions. Since 2008, Portugal has been participating in the I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) project with the EuroEVA study, which main objective is to estimate seasonal and pandemic vaccine effectiveness during and after the influenza season. In this context, we used two methods to estimate VE for the 2010-11 seasonal influenza vaccine, both in the elderly and in all age groups. Methods: Two approaches were used to estimate VE: the Test Negative Design (TND) and the Screnning method (SM). For TND, laboratory-confirmed influenza cases (ILI+) were compared to laboratory-negative influenza ILI patients (ILI-). ILI cases were selected by general practitioners using systematic sampling. For SM, the vaccine coverage (VC) on the ILI+ cases (recruited from the TND) was compared to the VC estimated in the general population using a telephone survey (ECOS). Results: Overall results obtained by the EuroEVA study indicate that crude 2010-11 seasonal VE estimate was 79% (CI95% 43-94) and 70% (CI95% 32-87) for the TND and SM...

Case control study for measuring influenza vaccine effectiveness in Portugal - Season 2010-11- Final report

Nunes, Baltazar; Pechirra, Pedro; Machado, Ausenda; Falcão, Isabel; Gonçalves, Paulo; Conde, Patricia; Batista, Inês; Guiomar, Raquel; Marinho Falcão, José
Fonte: Instituto Nacional de Saúde Doutor Ricardo Jorge, IP Publicador: Instituto Nacional de Saúde Doutor Ricardo Jorge, IP
Tipo: Relatório
Publicado em 01/06/2011 ENG
Relevância na Pesquisa
66.47%
Every year, influenza virus is responsible for epidemics that affect human health causing respiratory infections that could lead to serious health complications of individuals belonging to risk groups, as well as on the functioning of health services. In order to mitigate influenza impacts, vaccination has been one of the main measures, being recognized its role in reducing the risk of developing the disease and the occurrence of their complications. Thus, since the vaccine is reformulated every season estimating the influenza vaccine effectiveness (VE) every season and in an early stage is of major importance to support public health decisions. Since 2008-2009, Portugal has been participating in I-MOVE project that aims to estimate seasonal and pandemic vaccine effectiveness during and after the influenza season. Last season, 2010-2011, Portugal once again joined the I-MOVE multi-center case control study (with the national VE study- Euroeva) together with Spain, Ireland, France, Italy, Romania, Hungary and Poland, using a common protocol and with the objective of estimate the 2010-11 seasonal influenza vaccine effectiveness respectively in the elderly (65+) and in all age groups. Additionally, using information on 2010-11 seasonal vaccine coverage in the population...

Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13

Kissling, E.; Valenciano, M.; Buchholz, U.; Larrauri, A.; Cohen, J.M.; Nunes, Baltazar; Rogalska, J.; Pitigoi, D.; Paradowska-Stankiewicz, I.; Reuss, J.; Jiménez-Jorge, S.; Daviaud, I.; Guiomar, R.; O'Donnell, J.; Necula, G.; Głuchowska, M.; Moren, A.
Fonte: ECDC-European Centre for Disease Prevention and Control Publicador: ECDC-European Centre for Disease Prevention and Control
Tipo: Artigo de Revista Científica
Publicado em 13/02/2014 ENG
Relevância na Pesquisa
66.32%
In the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a multicentre case–control study (MCCS) in seven European Union (EU) Member States to measure 2012/13 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory confirmed as influenza. The season was characterised by substantial co-circulation of influenza B, A(H1N1)pdm09 and A(H3N2) viruses. Practitioners systematically selected ILI patients to swab ≤7 days of symptom onset. We compared influenza-positive by type/subtype to influenza-negative patients among those who met the EU ILI case definition. We conducted a complete case analysis using logistic regression with study as fixed effect and calculated adjusted vaccine effectiveness (AVE), controlling for potential confounders (age, sex, symptom onset week and presence of chronic conditions). We calculated AVE by type/subtype. Study sites sent 7,954 ILI/acute respiratory infection records for analysis. After applying exclusion criteria, we included 4,627 ILI patients in the analysis of VE against influenza B (1,937 cases), 3,516 for A(H1N1)pdm09 (1,068 cases) and 3,340 for influenza A(H3N2) (730 cases). AVE was 49.3% (95% confidence interval (CI): 32.4 to 62.0) against influenza B...

Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study

Kissling, E.; Valenciano, M.; Larrauri, A.; Oroszi, B.; Cohen, J.M.; Nunes, Baltazar; Pitigoi, D.; Rizzo, C.; Rebolledo, J.; Paradowska-Stankiewicz, I.; Jiménez-Jorge, S.; Horváth, J.K.; Daviaud, I.; Guiomar, Raquel; Necula, G.; Bella, A.; O'Donnell, J.
Fonte: ECDC-European Centre for Disease Prevention and Control Publicador: ECDC-European Centre for Disease Prevention and Control
Tipo: Artigo de Revista Científica
Publicado em 31/01/2013 ENG
Relevância na Pesquisa
56.29%
Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a multicentre case–control study in eight European Union (EU) Member States to estimate the 2011/12 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza A(H3) among the vaccination target groups. Practitioners systematically selected ILI / acute respiratory infection patients to swab within seven days of symptom onset. We restricted the study population to those meeting the EU ILI case definition and compared influenza A(H3) positive to influenza laboratory-negative patients. We used logistic regression with study site as fixed effect and calculated adjusted influenza vaccine effectiveness (IVE), controlling for potential confounders (age group, sex, month of symptom onset, chronic diseases and related hospitalisations, number of practitioner visits in the previous year). Adjusted IVE was 25% (95% confidence intervals (CI): -6 to 47) among all ages (n=1,014), 63% (95% CI: 26 to 82) in adults aged between 15 and 59 years and 15% (95% CI: -33 to 46) among those aged 60 years and above. Adjusted IVE was 38% (95%CI: -8 to 65) in the early influenza season (up to week 6 of 2012) and -1% (95% CI: -60 to 37) in the late phase. The results suggested a low adjusted IVE in 2011/12. The lower IVE in the late season could be due to virus changes through the season or waning immunity. Virological surveillance should be enhanced to quantify change over time and understand its relation with duration of immunological protection. Seasonal influenza vaccines should be improved to achieve acceptable levels of protection.; ECDC

Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection : two case-control studies, Spain, season 2009-2010

Savulescu, Camelia; Jiménez-Jorge, Silvia; Mateo, Salvador de; Pozo, Francisco; Casas, Inmaculada; Pérez Breña, Pilar; Galmés, Antonia; Vanrell, Juana M.; Rodriguez, Carolina; Vega, Tomás; Martínez, Ana; Torner, Nuria; Ramos, Julián M.; Serrano, Ma
Fonte: Universidade Autônoma de Barcelona Publicador: Universidade Autônoma de Barcelona
Tipo: Artigo de Revista Científica Formato: application/pdf
Publicado em //2011 ENG
Relevância na Pesquisa
46.45%
Background: Physicians of the Spanish Influenza Sentinel Surveillance System report and systematically swab patients attended to their practices for influenza-like illness (ILI). Within the surveillance system, some Spanish regions also participated in an observational study aiming at estimating influenza vaccine effectiveness (cycEVA study). During the season 2009-2010, we estimated pandemic influenza vaccine effectiveness using both the influenza surveillance data and the cycEVA study. Methods: We conducted two case-control studies using the test-negative design, between weeks 48/2009 and 8/2010 of the pandemic season. The surveillance-based study included all swabbed patients in the sentinel surveillance system. The cycEVA study included swabbed patients from seven Spanish regions. Cases were laboratory-confirmed pandemic influenza A(H1N1)2009. Controls were ILI patients testing negative for any type of influenza. Variables collected in both studies included demographic data, vaccination status, laboratory results, chronic conditions, and pregnancy. Additionally, cycEVA questionnaire collected data on previous influenza vaccination, smoking, functional status, hospitalisations, visits to the general practitioners, and obesity. We used logistic regression to calculate adjusted odds ratios (OR)...

Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination

Jiménez Jorge, Silvia; Mateo, Salvador de; Delgado-Sanz, Concha; Pozo, Francisco; Casas, Inmaculada; García Cenoz, Manuel; Castilla, Jesús; Pérez, Esteban; Gallardo, Virtudes; Rodriguez, Carolina; Vega, Tomás; Quiñones, Carmen; Martínez, Eva; Vanre
Fonte: Universidade Autônoma de Barcelona Publicador: Universidade Autônoma de Barcelona
Tipo: Artigo de Revista Científica Formato: application/pdf
Publicado em //2013 ENG
Relevância na Pesquisa
56.34%
Background: In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using the observational study cycEVA conducted in the frame of the existing Spanish Influenza Sentinel Surveillance System. The objective of the study was to estimate influenza vaccine effectiveness (VE) against medically attended, laboratory-confirmed influenza-like illness (ILI) among the target groups for vaccination in Spain in the 2011–2012 season. We also studied influenza VE in the early (weeks 52/2011-7/2012) and late (weeks 8-14/2012) phases of the epidemic and according to time since vaccination. Methods: Medically attended patients with ILI were systematically swabbed to collect information on exposure, laboratory outcome and confounding factors. Patients belonging to target groups for vaccination and who were swabbed <8 days after symptom onset were included. Cases tested positive for influenza and controls tested negative for any influenza virus. To examine the effect of a late season, analyses were performed according to the phase of the season and according to the time between vaccination and symptoms onset. Results: The overall adjusted influenza VE against A(H3N2) was 45% (95% CI, 0–69). The estimated influenza VE was 52% (95% CI...

Ten-year performance of Influenzanet: ILI time series, risks, vaccine effects, and care-seeking behaviour

van Noort, Sander P.; Codeço, Cláudia T.; Koppeschaar, Carl E.; van Ranst, Marc; Paolotti, Daniela; Gomes, M. Gabriela M.
Fonte: Elsivier Science BV Publicador: Elsivier Science BV
Tipo: Artigo de Revista Científica
Publicado em //2015 ENG
Relevância na Pesquisa
56.1%
Recent public health threats have propelled major innovations on infectious disease monitoring, culminating in the development of innovative syndromic surveillance methods. Influenzanet is an internet-based system that monitors influenza-like illness (ILI) in cohorts of self-reporting volunteers in European countries since 2003. We investigate and confirm coherence through the first ten years in comparison with ILI data from the European Influenza Surveillance Network and demonstrate country-specific behaviour of participants with ILI regarding medical care seeking. Using regression analysis, we determine that chronic diseases, being a child, living with children, being female, smoking and pets at home, are all independent predictors of ILI risk, whereas practicing sports and walking or bicycling for locomotion are associated with a small risk reduction. No effect for using public transportation or living alone was found. Furthermore, we determine the vaccine effectiveness for ILI for each season.; Institute for the Promotion of Innovation by Science and Technology (IWT - strategic basic research project SIMID), ICyT projects: (60/2010, 343/2010), Brazilian Research Council (CNPq), CAPES.

Influenza pandemic (H1N1) 2009 activity during summer 2009: Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain

Larrauri,Amparo; Savulescu,Camelia; Jiménez-Jorge,Silvia; Pérez-Breña,Pilar; Pozo,Francisco; Casas,Inmaculada; Ledesma,Juan; Mateo,Salvador de
Fonte: Gaceta Sanitaria Publicador: Gaceta Sanitaria
Tipo: info:eu-repo/semantics/article; journal article; info:eu-repo/semantics/publishedVersion Formato: text/html; application/pdf
Publicado em 01/02/2011 ENG
Relevância na Pesquisa
56.38%
Introduction: The Spanish influenza surveillance system (SISS) maintained its activity during the summer of 2009 to monitor the influenza pandemic. Objectives: To describe pandemic influenza activity from May to September 2009 and to estimate the effectiveness of the 2008-9 seasonal influenza vaccine against laboratory-confirmed pandemic (H1N1) 2009 influenza. Methods: Data from the SISS were used to identify the trend of pandemic (H1N1) 2009 influenza outside the influenza season. For the effectiveness study, we compared the vaccination status of notified cases [influenza-like illnesses (ILI) laboratory confirmed as pandemic influenza] with that of the test-negative controls. Results: The first laboratory-confirmed case of the pandemic virus was notified in the system in week 20/2009. The ILI rate increased gradually in the study period, exceeding basic activity in week 38. The proportion of pandemic (H1N1) 2009 influenza viruses detected by the system represented 14% in week 20/2009 and rapidly increased to 90% in week 34. The adjusted vaccine effectiveness of the 2008-9 seasonal vaccine against laboratory-confirmed pandemic influenza was 12% (-30; 41). Conclusions: The SISS became an essential tool for pandemic monitoring in Spain. The improved SISS will provide more accurate information on influenza activity in future seasonal or pandemic waves. Using surveillance data...

Influenza pandemic (H1N1) 2009 activity during summer 2009: Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain

Larrauri,Amparo; Savulescu,Camelia; Jiménez-Jorge,Silvia; Pérez-Breña,Pilar; Pozo,Francisco; Casas,Inmaculada; Ledesma,Juan; Mateo,Salvador de
Fonte: Ediciones Doyma, S.L. Publicador: Ediciones Doyma, S.L.
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/02/2011 EN
Relevância na Pesquisa
56.38%
Introduction: The Spanish influenza surveillance system (SISS) maintained its activity during the summer of 2009 to monitor the influenza pandemic. Objectives: To describe pandemic influenza activity from May to September 2009 and to estimate the effectiveness of the 2008-9 seasonal influenza vaccine against laboratory-confirmed pandemic (H1N1) 2009 influenza. Methods: Data from the SISS were used to identify the trend of pandemic (H1N1) 2009 influenza outside the influenza season. For the effectiveness study, we compared the vaccination status of notified cases [influenza-like illnesses (ILI) laboratory confirmed as pandemic influenza] with that of the test-negative controls. Results: The first laboratory-confirmed case of the pandemic virus was notified in the system in week 20/2009. The ILI rate increased gradually in the study period, exceeding basic activity in week 38. The proportion of pandemic (H1N1) 2009 influenza viruses detected by the system represented 14% in week 20/2009 and rapidly increased to 90% in week 34. The adjusted vaccine effectiveness of the 2008-9 seasonal vaccine against laboratory-confirmed pandemic influenza was 12% (-30; 41). Conclusions: The SISS became an essential tool for pandemic monitoring in Spain. The improved SISS will provide more accurate information on influenza activity in future seasonal or pandemic waves. Using surveillance data...

Measles vaccine effectiveness and risk factors for measles in Dhaka, Bangladesh

Akramuzzaman,Syed M.; Cutts,Felicity T.; Hossain,Md J.; Wahedi,Obaidullah K.; Nahar,Nazmun; Islam,Darul; Shaha,Narayan C.; Mahalanabis,Dilip
Fonte: World Health Organization Publicador: World Health Organization
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/10/2002 EN
Relevância na Pesquisa
56.25%
OBJECTIVE: To evaluate vaccine effectiveness and to assess risk factors for measles in Dhaka, Bangladesh. METHOD: A case-control study, involving 198 cases with 783 age-matched neighbourhood controls and 120 measles cases with 365 age-matched hospital controls, was conducted in 1995-96 in three large hospitals in Dhaka. FINDINGS: Measles vaccine effectiveness was estimated at 80% (95% confidence interval (CI) = 60-90%) using neighbourhood controls; very similar results were obtained using hospital controls. Visits to a health facility 7-21 days before onset of any symptoms were associated with increased risk of measles compared with neighbourhood (adjusted odds ratio (OR) = 7.0, 95% CI = 4.2-11.6) or hospital (adjusted OR = 1.7, 95% CI = 1.01-2.8) controls. Cases were more likely than controls to come from a household where more than one child lived (adjusted OR = 1.6, 95% CI = 1.1-2.5 versus neighbourhood controls; adjusted OR = 1.8, 95% CI = 1.02-3.0 versus hospital controls). CONCLUSIONS: To improve measles control in urban Dhaka missed immunization opportunities must be reduced in all health care facilities by following WHO guidelines. For measles elimination, more than one dose of vaccine would be required.